494 related articles for article (PubMed ID: 30053291)
21. Utility of copy number variants in the classification of intracranial ependymoma.
Evenson M; Cai C; Hucthagowder V; McNulty S; Neidich J; Kulkarni S; Dahiya S
Cancer Genet; 2020 Jan; 240():66-72. PubMed ID: 31794935
[TBL] [Abstract][Full Text] [Related]
22. Targeted fusion analysis can aid in the classification and treatment of pediatric glioma, ependymoma, and glioneuronal tumors.
Lake JA; Donson AM; Prince E; Davies KD; Nellan A; Green AL; Mulcahy Levy J; Dorris K; Vibhakar R; Hankinson TC; Foreman NK; Ewalt MD; Kleinschmidt-DeMasters BK; Hoffman LM; Gilani A
Pediatr Blood Cancer; 2020 Jan; 67(1):e28028. PubMed ID: 31595628
[TBL] [Abstract][Full Text] [Related]
23. Correlation of bcl-2, p53, and MIB-1 expression with ependymoma grade and subtype.
Rushing EJ; Brown DF; Hladik CL; Risser RC; Mickey BE; White CL
Mod Pathol; 1998 May; 11(5):464-70. PubMed ID: 9619600
[TBL] [Abstract][Full Text] [Related]
24. Clinical significance of the histological and molecular characteristics of ependymal tumors: a single institution case series from China.
Xi S; Sai K; Hu W; Wang F; Chen Y; Wang J; Zeng J; Chen Z
BMC Cancer; 2019 Jul; 19(1):717. PubMed ID: 31324163
[TBL] [Abstract][Full Text] [Related]
25. Recent Advances in the Classification and Treatment of Ependymomas.
Leeper H; Felicella MM; Walbert T
Curr Treat Options Oncol; 2017 Aug; 18(9):55. PubMed ID: 28795287
[TBL] [Abstract][Full Text] [Related]
26. Identification of relevant prognostic histopathologic features in 69 intracranial ependymomas, excluding myxopapillary ependymomas and subependymomas.
Kurt E; Zheng PP; Hop WC; van der Weiden M; Bol M; van den Bent MJ; Avezaat CJ; Kros JM
Cancer; 2006 Jan; 106(2):388-95. PubMed ID: 16342252
[TBL] [Abstract][Full Text] [Related]
27. Clinicopathologic study of 61 patients with ependymoma including MIB-1 immunohistochemistry.
Prayson RA
Ann Diagn Pathol; 1999 Feb; 3(1):11-8. PubMed ID: 9990108
[TBL] [Abstract][Full Text] [Related]
28. Comprehensive profiling of myxopapillary ependymomas identifies a distinct molecular subtype with relapsing disease.
Bockmayr M; Harnisch K; Pohl LC; Schweizer L; Mohme T; Körner M; Alawi M; Suwala AK; Dorostkar MM; Monoranu CM; Hasselblatt M; Wefers AK; Capper D; Hench J; Frank S; Richardson TE; Tran I; Liu E; Snuderl M; Engertsberger L; Benesch M; von Deimling A; Obrecht D; Mynarek M; Rutkowski S; Glatzel M; Neumann JE; Schüller U
Neuro Oncol; 2022 Oct; 24(10):1689-1699. PubMed ID: 35380708
[TBL] [Abstract][Full Text] [Related]
29. Chromosome 1q gain and tenascin-C expression are candidate markers to define different risk groups in pediatric posterior fossa ependymoma.
Araki A; Chocholous M; Gojo J; Dorfer C; Czech T; Heinzl H; Dieckmann K; Ambros IM; Ambros PF; Slavc I; Haberler C
Acta Neuropathol Commun; 2016 Aug; 4(1):88. PubMed ID: 27550150
[TBL] [Abstract][Full Text] [Related]
30. MYCN amplification drives an aggressive form of spinal ependymoma.
Ghasemi DR; Sill M; Okonechnikov K; Korshunov A; Yip S; Schutz PW; Scheie D; Kruse A; Harter PN; Kastelan M; Wagner M; Hartmann C; Benzel J; Maass KK; Khasraw M; Sträter R; Thomas C; Paulus W; Kratz CP; Witt H; Kawauchi D; Herold-Mende C; Sahm F; Brandner S; Kool M; Jones DTW; von Deimling A; Pfister SM; Reuss DE; Pajtler KW
Acta Neuropathol; 2019 Dec; 138(6):1075-1089. PubMed ID: 31414211
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of chromosome 1q gain in intracranial ependymomas.
Rajeshwari M; Sharma MC; Kakkar A; Nambirajan A; Suri V; Sarkar C; Singh M; Saran RK; Gupta RK
J Neurooncol; 2016 Apr; 127(2):271-8. PubMed ID: 26725097
[TBL] [Abstract][Full Text] [Related]
32. Novel fusion genes and chimeric transcripts in ependymal tumors.
Olsen TK; Panagopoulos I; Gorunova L; Micci F; Andersen K; Kilen Andersen H; Meling TR; Due-Tønnessen B; Scheie D; Heim S; Brandal P
Genes Chromosomes Cancer; 2016 Dec; 55(12):944-953. PubMed ID: 27401149
[TBL] [Abstract][Full Text] [Related]
33. Genomic characterization of ependymomas reveals 6q loss as the most common aberration.
Olsen TK; Gorunova L; Meling TR; Micci F; Scheie D; Due-Tønnessen B; Heim S; Brandal P
Oncol Rep; 2014 Aug; 32(2):483-90. PubMed ID: 24939246
[TBL] [Abstract][Full Text] [Related]
34. Histological spectrum of ependymomas and correlation of p53 and Ki-67 expression with ependymoma grade and subtype.
Suri VS; Tatke M; Singh D; Sharma A
Indian J Cancer; 2004; 41(2):66-71. PubMed ID: 15318011
[TBL] [Abstract][Full Text] [Related]
35. EANO guidelines for the diagnosis and treatment of ependymal tumors.
Rudà R; Reifenberger G; Frappaz D; Pfister SM; Laprie A; Santarius T; Roth P; Tonn JC; Soffietti R; Weller M; Moyal EC
Neuro Oncol; 2018 Mar; 20(4):445-456. PubMed ID: 29194500
[TBL] [Abstract][Full Text] [Related]
36. The histologic grade is a main prognostic factor for patients with intracranial ependymomas treated in the microneurosurgical era: an analysis of 258 patients.
Korshunov A; Golanov A; Sycheva R; Timirgaz V
Cancer; 2004 Mar; 100(6):1230-7. PubMed ID: 15022291
[TBL] [Abstract][Full Text] [Related]
37. Transcriptional profiling of paediatric ependymomas identifies prognostically significant groups.
Łastowska M; Matyja E; Sobocińska A; Wojtaś B; Niemira M; Szałkowska A; Krętowski A; Karkucińska-Więckowska A; Kaleta M; Ejmont M; Tarasińska M; Perek-Polnik M; Dembowska-Bagińska B; Pronicki M; Grajkowska W; Trubicka J
J Pathol Clin Res; 2021 Nov; 7(6):565-576. PubMed ID: 34314101
[TBL] [Abstract][Full Text] [Related]
38. A clinicopathologic study of 81 patients with ependymomas and proposal of diagnostic criteria for anaplastic ependymoma.
Ho DM; Hsu CY; Wong TT; Chiang H
J Neurooncol; 2001 Aug; 54(1):77-85. PubMed ID: 11763426
[TBL] [Abstract][Full Text] [Related]
39. [Detection of chromosomal imbalance in ependymoma by comparative genomic hybridization].
Wu WX; Yu SZ; Sun CY; Wang Q; Jin SM; An TL
Zhonghua Bing Li Xue Za Zhi; 2009 Mar; 38(3):148-52. PubMed ID: 19575847
[TBL] [Abstract][Full Text] [Related]
40. Latest classification of ependymoma in the molecular era and advances in its treatment: a review.
Yamaguchi J; Ohka F; Motomura K; Saito R
Jpn J Clin Oncol; 2023 Jul; 53(8):653-663. PubMed ID: 37288489
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
